Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03206073
Title A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

colorectal cancer

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.